300642 透景生命
已收盘 08-26 15:00:00
资讯
新帖
简况
股市必读:透景生命中报 - 第二季度单季净利润同比增长644.77%
证券之星 · 01:11
股市必读:透景生命中报 - 第二季度单季净利润同比增长644.77%
透景生命(300642)披露2026年中期利润分配方案,8月25日股价上涨20.0%
证券之星 · 08-25 17:33
透景生命(300642)披露2026年中期利润分配方案,8月25日股价上涨20.0%
图解透景生命中报:第二季度单季净利润同比增长644.77%
证券之星 · 08-25 02:52
图解透景生命中报:第二季度单季净利润同比增长644.77%
股市必读:透景生命新发布《关于申报医疗器械注册获得受理的公告》
证券之星 · 08-13
股市必读:透景生命新发布《关于申报医疗器械注册获得受理的公告》
透景生命(300642)披露6项医疗器械注册申请获受理,8月12日股价上涨0.44%
证券之星 · 08-12
透景生命(300642)披露6项医疗器械注册申请获受理,8月12日股价上涨0.44%
透景生命(300642)披露完成注册地址工商变更及投资者联系方式变更公告,8月11日股价下跌1.52%
证券之星 · 08-11
透景生命(300642)披露完成注册地址工商变更及投资者联系方式变更公告,8月11日股价下跌1.52%
透景生命(300642)披露取得医疗器械变更注册文件及多项注册申请获受理公告,8月6日股价上涨0.7%
证券之星 · 08-06
透景生命(300642)披露取得医疗器械变更注册文件及多项注册申请获受理公告,8月6日股价上涨0.7%
7月21日透景生命发生1笔大宗交易 成交金额229.91万元
证券之星 · 07-21
7月21日透景生命发生1笔大宗交易 成交金额229.91万元
股市必读:7月17日透景生命现209.96万元大宗交易
证券之星 · 07-20
股市必读:7月17日透景生命现209.96万元大宗交易
透景生命(300642)披露子公司注销医疗器械注册证公告,7月17日股价下跌7.5%
证券之星 · 07-17
透景生命(300642)披露子公司注销医疗器械注册证公告,7月17日股价下跌7.5%
透景生命(300642)披露部分股票期权及限制性股票注销完成公告,6月30日股价下跌2.88%
证券之星 · 06-30
透景生命(300642)披露部分股票期权及限制性股票注销完成公告,6月30日股价下跌2.88%
透景生命最新公告:全资子公司取得医疗器械注册证
证券之星 · 06-29
透景生命最新公告:全资子公司取得医疗器械注册证
透景生命(300642)披露申报医疗器械注册获得受理的公告,5月26日股价下跌2.09%
证券之星 · 05-26
透景生命(300642)披露申报医疗器械注册获得受理的公告,5月26日股价下跌2.09%
透景生命(300642.SZ):人类免疫缺陷病毒抗原抗体联合检测试剂盒(化学发光免疫分析法)医疗器械注册获受理
智通财经 · 05-25
透景生命(300642.SZ):人类免疫缺陷病毒抗原抗体联合检测试剂盒(化学发光免疫分析法)医疗器械注册获受理
透景生命最新公告:控股子公司通过高新技术企业重新认定
证券之星 · 05-19
透景生命最新公告:控股子公司通过高新技术企业重新认定
透景生命(300642)股东凌飞集团有限公司质押1100万股,占总股本6.77%
证券之星 · 05-06
透景生命(300642)股东凌飞集团有限公司质押1100万股,占总股本6.77%
透景生命(300642)披露持股5%以上股东股份解除质押及再质押公告,5月6日股价上涨0.3%
证券之星 · 05-06
透景生命(300642)披露持股5%以上股东股份解除质押及再质押公告,5月6日股价上涨0.3%
每周股票复盘:透景生命(300642)推进国际化布局与新品研发
证券之星 · 05-03
每周股票复盘:透景生命(300642)推进国际化布局与新品研发
透景生命:商誉减值测试经专业评估和审计核查
证券之星 · 04-29
透景生命:商誉减值测试经专业评估和审计核查
透景生命(300642)3月31日股东户数1.98万户,较上期增加4.83%
证券之星 · 04-25
透景生命(300642)3月31日股东户数1.98万户,较上期增加4.83%
加载更多
公司概况
公司名称:
上海透景生命科技股份有限公司
所属行业:
医药制造业
上市日期:
2017-04-21
主营业务:
上海透景生命科技股份有限公司的主营业务是自主品牌体外诊断产品的研发、生产与销售。公司的主要产品是肿瘤检测产品、自身免疫检测产品、心血管疾病检测产品、甲功激素检测产品、真菌检测产品。公司与国内外众多知名院校开展合作,并设有国家级博士后科研工作站,依托各方研究特色和优势,为科研人员提供了产学研用一体化的、具有国际水准的平台。
发行价格:
36.10
{"stockData":{"symbol":"300642","market":"SZ","secType":"STK","nameCN":"透景生命","latestPrice":17.24,"timestamp":1787727792000,"preClose":16.2,"halted":0,"volume":39028831,"delay":0,"changeRate":0.0642,"floatShares":138000000,"shares":162000000,"eps":0.0759,"marketStatus":"已收盘","change":1.04,"latestTime":"08-26 15:00:00","open":16.88,"high":18.81,"low":16.27,"amount":678000000,"amplitude":0.1568,"askPrice":17.25,"askSize":23,"bidPrice":17.24,"bidSize":32,"shortable":0,"etf":0,"ttmEps":0.0759,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1787794200000},"marketStatusCode":5,"adr":0,"adjPreClose":16.2,"symbolType":"stock","openAndCloseTimeList":[[1787707800000,1787715000000],[1787720400000,1787727600000]],"highLimit":17.82,"lowLimit":14.58,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":162272241,"isCdr":false,"pbRate":1.83,"roa":"--","peRate":227.140975,"roe":"0.8%","epsLYR":0.022,"committee":0.846535,"marketValue":2798000000,"turnoverRate":0.2834,"status":0,"floatMarketCap":2374000000},"requestUrl":"/m/hq/s/300642","defaultTab":"news","newsList":[{"id":"2662568759","title":"股市必读:透景生命中报 - 第二季度单季净利润同比增长644.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662568759","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662568759?lang=zh_cn&edition=full","pubTime":"2026-08-26 01:11","pubTimestamp":1787677873,"startTime":"0","endTime":"0","summary":"股本股东变化:截至2026年6月30日股东户数降至1.71万户,较上期减少13.21%,户均持股增至9466.0股。业绩披露要点:2026年第二季度归母净利润1703.73万元,同比大增644.77%;扣非净利润1293.94万元,同比激增3604.04%。本次变动增加公司2026年半年度利润总额8,535,815.52元,增加净利润7,244,750.37元。2026年半年度非经营性资金占用及其他关联资金往来情况汇总表上海透景生命科技股份有限公司披露2026年半年度非经营性资金占用及其他关联资金往来情况。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600003248.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300642"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662081780","title":"透景生命(300642)披露2026年中期利润分配方案,8月25日股价上涨20.0%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662081780","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662081780?lang=zh_cn&edition=full","pubTime":"2026-08-25 17:33","pubTimestamp":1787650402,"startTime":"0","endTime":"0","summary":"截至2026年8月25日收盘,透景生命报收于16.2元,较前一交易日上涨20.0%,最新总市值为26.29亿元。该股当日开盘14.3元,最高16.2元,最低14.3元,成交额达1.79亿元,换手率为8.18%。近日,上海透景生命科技股份有限公司发布《关于2026年中期利润分配方案的公告》。该方案已获第四届董事会第十七次会议审议通过,并经2025年度股东会授权,无需提交股东会审议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082500036206.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300642","BK0042","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662220322","title":"图解透景生命中报:第二季度单季净利润同比增长644.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662220322","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662220322?lang=zh_cn&edition=full","pubTime":"2026-08-25 02:52","pubTimestamp":1787597559,"startTime":"0","endTime":"0","summary":"证券之星消息,透景生命2026年中报显示,上半年度公司主营收入1.87亿元,同比上升17.78%;归母净利润1147.65万元,同比上升315.92%;扣非净利润595.24万元,同比上升419.31%;其中2026年第二季度,公司单季度主营收入1.05亿元,同比上升24.44%;单季度归母净利润1703.73万元,同比上升644.77%;单季度扣非净利润1293.94万元,同比上升3604.04%;负债率26.73%,投资收益-599.18万元,财务费用377.5万元,毛利率67.04%。财报数据概要请见下图:本文数据来源于透景生命2026年中报,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082500005616.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300642"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659876902","title":"股市必读:透景生命新发布《关于申报医疗器械注册获得受理的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2659876902","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659876902?lang=zh_cn&edition=full","pubTime":"2026-08-13 02:27","pubTimestamp":1786559231,"startTime":"0","endTime":"0","summary":"公司公告汇总:透景生命及控股子公司脉示生物共6项医疗器械注册申请获上海市药监局受理,涉及阿尔茨海默病辅助诊断及激素、维生素检测等领域。产品包括用于阿尔茨海默病辅助诊断的β淀粉样蛋白和磷酸化Tau蛋白测定试剂盒,以及用于激素水平异常和脂溶性维生素评价的测定试剂盒。上述产品处于注册申请受理阶段,后续需经技术审评、行政审批等流程。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081300001600.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300642","BK0239","BK0046","BK1583","159883","BK1574","09996","BK0042","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658905980","title":"透景生命(300642)披露6项医疗器械注册申请获受理,8月12日股价上涨0.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658905980","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658905980?lang=zh_cn&edition=full","pubTime":"2026-08-12 22:35","pubTimestamp":1786545316,"startTime":"0","endTime":"0","summary":"截至2026年8月12日收盘,透景生命报收于13.64元,较前一交易日上涨0.44%,最新总市值为22.13亿元。该股当日开盘13.64元,最高13.85元,最低13.5元,成交额达3842.23万元,换手率为2.04%。公告显示,上海透景生命科技股份有限公司及控股子公司上海脉示生物技术有限公司申报的6项医疗器械注册申请已获上海市药品监督管理局受理。上述产品处于注册申请受理阶段,后续需经技术审评、行政审批等流程。该事项对公司近期业绩无直接影响,最终是否获批存在不确定性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081200040363.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","09996","BK0046","BK1100","BK1574","BK1583","BK0239","300642","159883"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658916096","title":"透景生命(300642)披露完成注册地址工商变更及投资者联系方式变更公告,8月11日股价下跌1.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658916096","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658916096?lang=zh_cn&edition=full","pubTime":"2026-08-11 22:22","pubTimestamp":1786458140,"startTime":"0","endTime":"0","summary":"截至2026年8月11日收盘,透景生命报收于13.58元,较前一交易日下跌1.52%,最新总市值为22.04亿元。该股当日开盘13.84元,最高13.85元,最低13.4元,成交额达6607.93万元,换手率为3.53%。公司于近日披露《关于完成注册地址工商变更及投资者联系方式变更的公告》。公告显示,上海透景生命科技股份有限公司已完成注册地址工商变更,注册地址由上海市浦东新区汇庆路412号变更为上海市浦东新区凯庆路126号,并取得新的营业执照。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081100038377.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","300642","BK0042"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657681698","title":"透景生命(300642)披露取得医疗器械变更注册文件及多项注册申请获受理公告,8月6日股价上涨0.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657681698","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657681698?lang=zh_cn&edition=full","pubTime":"2026-08-06 17:32","pubTimestamp":1786008740,"startTime":"0","endTime":"0","summary":"截至2026年8月6日收盘,透景生命报收于12.88元,较前一交易日上涨0.7%,最新总市值为20.9亿元。公司于近日披露《关于取得医疗器械变更注册(备案)文件及申报医疗器械注册获得受理的公告》。公告显示,上海透景生命科技股份有限公司近日取得国家药品监督管理局颁发的《医疗器械变更注册(备案)文件》,完成人SHOX2、RASSF1A基因甲基化DNA检测试剂盒的变更,新增痰液、胸腔积液样本类型,适用于肺癌疑似人群的辅助诊断。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080600029106.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1583","BK1100","159883","300642","BK0239","BK0046","BK1574","09996","BK0042"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653273023","title":"7月21日透景生命发生1笔大宗交易 成交金额229.91万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2653273023","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653273023?lang=zh_cn&edition=full","pubTime":"2026-07-21 17:52","pubTimestamp":1784627567,"startTime":"0","endTime":"0","summary":"证券之星消息,7月21日透景生命发生大宗交易,交易数据如下:大宗交易成交价格11.79元,成交19.5万股,成交金额229.91万元,买方营业部为中信建投证券股份有限公司杭州庆春路证券营业部,卖方营业部为中信建投证券股份有限公司杭州庆春路证券营业部。近三个月该股共发生2笔大宗交易,合计成交3619.0手。截至2026年7月21日收盘,透景生命报收于11.79元,下跌2.88%,换手率4.9%,成交量6.75万手,成交额7845.71万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072100033058.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300642","BK0239","BK0042","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652925714","title":"股市必读:7月17日透景生命现209.96万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2652925714","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652925714?lang=zh_cn&edition=full","pubTime":"2026-07-20 02:36","pubTimestamp":1784486171,"startTime":"0","endTime":"0","summary":"截至2026年7月17日收盘,透景生命报收于12.58元,下跌7.5%,换手率3.93%,成交量5.42万手,成交额7036.37万元。公司公告汇总:全资子公司湖南透景生命科技有限公司于7月10日完成26项医疗器械注册证注销,相关产品已由江西透景承接并具备生产条件。大宗交易7月17日透景生命发生一笔209.96万元大宗交易。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072000001239.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300642","BK0042","BK0239","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652281853","title":"透景生命(300642)披露子公司注销医疗器械注册证公告,7月17日股价下跌7.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2652281853","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652281853?lang=zh_cn&edition=full","pubTime":"2026-07-17 22:45","pubTimestamp":1784299516,"startTime":"0","endTime":"0","summary":"截至2026年7月17日收盘,透景生命报收于12.58元,较前一交易日下跌7.5%,最新总市值为20.41亿元。公司于近日披露《关于子公司注销医疗器械注册证的公告》。公告显示,上海透景生命科技股份有限公司全资子公司湖南透景生命科技有限公司因公司整体业务布局优化与内部资源整合,于2026年7月10日完成26项医疗器械注册证的注销手续。上述产品前期已由公司全资子公司江西透景生命科技有限公司报批并取得相关注册证,江西透景已具备相应的生产条件。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071700045212.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1583","BK0239","BK1574","09996","BK1100","159883","BK0042","300642","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647534792","title":"透景生命(300642)披露部分股票期权及限制性股票注销完成公告,6月30日股价下跌2.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2647534792","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2647534792?lang=zh_cn&edition=full","pubTime":"2026-06-30 18:01","pubTimestamp":1782813719,"startTime":"0","endTime":"0","summary":"截至2026年6月30日收盘,透景生命报收于11.8元,较前一交易日下跌2.88%,最新总市值为19.15亿元。该股当日开盘12.03元,最高12.19元,最低11.69元,成交额达5282.59万元,换手率为3.23%。近日,上海透景生命科技股份有限公司发布《关于部分股票期权注销完成和部分限制性股票回购注销完成的公告》。公告显示,公司注销股票期权887,400份,涉及45人;回购注销限制性股票271,800股,回购价格10.55元/股,总金额2,867,490元。相关手续已办理完毕,公司总股本由162,544,041股减少至162,272,241股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026063000034188.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300642","BK0042","BK0046","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647202703","title":"透景生命最新公告:全资子公司取得医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2647202703","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2647202703?lang=zh_cn&edition=full","pubTime":"2026-06-29 17:51","pubTimestamp":1782726662,"startTime":"0","endTime":"0","summary":"透景生命(300642.SZ)公告称,公司全资子公司江西透景生命科技有限公司近日取得江西省药品监督管理局颁发的1项医疗器械注册证,产品为全自动化学发光免疫分析仪(型号TESMIi60、TESMIi60M),注册证有效期至2031年6月17日。该注册证将丰富公司化学发光产品线,拓展应用场景,增强体外诊断领域竞争力,但未来业绩影响存在不确定性。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900028167.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","09996","159883","300642","BK1100","BK1583","BK0239","BK1574","BK0042"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638590765","title":"透景生命(300642)披露申报医疗器械注册获得受理的公告,5月26日股价下跌2.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2638590765","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2638590765?lang=zh_cn&edition=full","pubTime":"2026-05-26 17:32","pubTimestamp":1779787969,"startTime":"0","endTime":"0","summary":"截至2026年5月26日收盘,透景生命报收于14.54元,较前一交易日下跌2.09%,最新总市值为23.63亿元。该股当日开盘14.95元,最高14.96元,最低14.38元,成交额达5323.16万元,换手率为2.65%。近日,上海透景生命科技股份有限公司发布公告称,其申报的“人类免疫缺陷病毒抗原抗体联合检测试剂盒”已获国家药品监督管理局受理。当前处于注册申请受理阶段,后续需经技术审评、行政审批等流程。该事项对公司近期业绩无影响,最终是否获批取决于国家药监局审评结论。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052600030069.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1100","09996","BK0046","300642","BK0042","BK0239","159883","BK1583","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638213530","title":"透景生命(300642.SZ):人类免疫缺陷病毒抗原抗体联合检测试剂盒(化学发光免疫分析法)医疗器械注册获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2638213530","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2638213530?lang=zh_cn&edition=full","pubTime":"2026-05-25 20:16","pubTimestamp":1779711369,"startTime":"0","endTime":"0","summary":"智通财经APP讯,透景生命 发布公告,公司申报的医疗器械注册申请于近日获得了国家药品监督管理局的受理,该产品为:“人类免疫缺陷病毒抗原抗体联合检测试剂盒”。上述受理产品可检测出HIV-1 P24抗原以及HIV-1型、HIV-2型以及HIV-1 型O组抗体,能更早的检测到HIV病毒感染状况,用于临床HIV-1型病毒和HIV-2 型病毒感染的辅助诊断。检测结果不具体区分HIV-1P24抗原、HIV-1抗体、HIV-2 抗体或HIV-1型O组抗体反应性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1445698.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK0042","BK0046","BK0239","BK1100","159883","300642","09996","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636685345","title":"透景生命最新公告:控股子公司通过高新技术企业重新认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2636685345","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2636685345?lang=zh_cn&edition=full","pubTime":"2026-05-19 19:29","pubTimestamp":1779190188,"startTime":"0","endTime":"0","summary":"透景生命(300642.SZ)公告称,公司控股子公司武汉康录生物技术股份有限公司近日收到湖北省相关部门联合颁发的《高新技术企业证书》,有效期三年。康录生物自2025年度至2027年度将继续享受按15%税率缴纳企业所得税的税收优惠政策。由于2025年度已暂按15%税率计提所得税,该政策不会对公司2025年已披露财务数据造成影响。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051900037520.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","300642","BK0239","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633181860","title":"透景生命(300642)股东凌飞集团有限公司质押1100万股,占总股本6.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633181860","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2633181860?lang=zh_cn&edition=full","pubTime":"2026-05-06 18:28","pubTimestamp":1778063304,"startTime":"0","endTime":"0","summary":"证券之星消息,透景生命5月6日公开信息显示,股东凌飞集团有限公司向上海浦东发展银行股份有限公司杭州萧山支行合计质押1100.0万股,占总股本6.77%。透景生命主营业务:自主品牌的体外诊断产品的研发、生产和销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050600032211.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","300642","BK0042","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633868681","title":"透景生命(300642)披露持股5%以上股东股份解除质押及再质押公告,5月6日股价上涨0.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633868681","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2633868681?lang=zh_cn&edition=full","pubTime":"2026-05-06 17:59","pubTimestamp":1778061544,"startTime":"0","endTime":"0","summary":"上海透景生命科技股份有限公司于2026年5月6日发布公告,持股5%以上股东凌飞集团有限公司将其持有的11,000,000股公司股份办理了解除质押手续,并于2026年4月22日重新质押11,000,000股,占其所持股份比例91.39%,占公司总股本比例6.77%,质权人为上海浦东发展银行股份有限公司杭州萧山支行,质押用途为自身生产经营。截至公告日,凌飞集团资信状况良好,质押风险可控,所质押股份不存在平仓风险。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050600028583.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300642","BK0042","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632611608","title":"每周股票复盘:透景生命(300642)推进国际化布局与新品研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2632611608","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2632611608?lang=zh_cn&edition=full","pubTime":"2026-05-03 08:17","pubTimestamp":1777767433,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘,透景生命报收于16.51元,较上周的16.7元下跌1.14%。本周,透景生命4月29日盘中最高价报16.88元。公司在营销端进一步明确了重点布局的产品,包括FISH产品、自身免疫产品、真菌检测和分子POCT产品线。FISH产品由控股子公司康录生物进行推广,公司将持续推进其在分子病理赛道的发展,推动仪器自动化,提升市场份额与客户粘性,巩固细分领域优势地位。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050300002047.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","300642","BK0042","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631955256","title":"透景生命:商誉减值测试经专业评估和审计核查","url":"https://stock-news.laohu8.com/highlight/detail?id=2631955256","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2631955256?lang=zh_cn&edition=full","pubTime":"2026-04-29 11:37","pubTimestamp":1777433875,"startTime":"0","endTime":"0","summary":"证券之星消息,透景生命04月28日在投资者关系平台上答复投资者关心的问题。投资者提问:2025年,公司商誉达到总资产的9.00%,但商誉减值准备只有0.17%,请问公司是否存在利用商誉减值调节利润的可能?商誉减值测试的关键在于是否存在客观迹象表明包含商誉的资产组的可收回金额低于其账面价值,相关资产组合均已经过银信资产评估有限公司进行专业评估。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042900037783.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","BK0042","300642"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630706358","title":"透景生命(300642)3月31日股东户数1.98万户,较上期增加4.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630706358","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2630706358?lang=zh_cn&edition=full","pubTime":"2026-04-25 17:12","pubTimestamp":1777108358,"startTime":"0","endTime":"0","summary":"证券之星消息,近日透景生命披露,截至2026年3月31日公司股东户数为1.98万户,较12月31日增加911.0户,增幅为4.83%。在医疗器械行业个股中,透景生命股东户数低于行业平均水平,截至3月31日,医疗器械行业平均股东户数为2.19万户。从股价来看,2025年12月31日至2026年3月31日,透景生命区间跌幅为10.06%,在此期间股东户数增加911.0户,增幅为4.83%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042500032704.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0042","300642","BK0046"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1787752440708,"stockEarnings":[{"period":"1week","weight":0.179},{"period":"1month","weight":0.4439},{"period":"3month","weight":0.1384},{"period":"6month","weight":-0.1114},{"period":"1year","weight":-0.4328},{"period":"ytd","weight":-0.1133}],"compareEarnings":[{"period":"1week","weight":-0.0253},{"period":"1month","weight":0.0197},{"period":"3month","weight":-0.0499},{"period":"6month","weight":-0.062},{"period":"1year","weight":0.0015},{"period":"ytd","weight":-0.02}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海透景生命科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"17143人(较上一季度减少13.21%)","perCapita":"8032股","listingDate":"2017-04-21","address":"上海市浦东新区凯庆路126号","registeredCapital":"16227万元","survey":" 上海透景生命科技股份有限公司的主营业务是自主品牌体外诊断产品的研发、生产与销售。公司的主要产品是肿瘤检测产品、自身免疫检测产品、心血管疾病检测产品、甲功激素检测产品、真菌检测产品。公司与国内外众多知名院校开展合作,并设有国家级博士后科研工作站,依托各方研究特色和优势,为科研人员提供了产学研用一体化的、具有国际水准的平台。","listedPrice":36.1},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"透景生命(300642)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供透景生命(300642)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"透景生命,300642,透景生命股票,透景生命股票老虎,透景生命股票老虎国际,透景生命行情,透景生命股票行情,透景生命股价,透景生命股市,透景生命股票价格,透景生命股票交易,透景生命股票购买,透景生命股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"透景生命(300642)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供透景生命(300642)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}